Sentence examples for gag level from inspiring English sources

To evaluate the efficacy of tenofovir gel, vehicle control gel, or tenofovir in ectocervical and colorectal explant cultures, comparisons of log10 transformed p24gag levels with controls (HIV-1 only) were performed at time-points with peak median p24 gag level for control (HIV-1 only) group.

Samples were read at 595 nm and the GAG level determined from a linear standard curve (12.5 to 400 μg/ml).

TGF-β1-stimulated cultures showed a higher GAG level than fresh cartilage after two weeks; this decreased during further culture to levels below those of fresh cartilage.

Therefore, if clinical suspicion of MPS is high but the urinary GAG level is normal, additional diagnostic testing should be pursued (Fig.  4).

The mean urinary GAG level was 2.5 ± 2.09 mg/mmol creatinine (range, 0.45 9.96) in the control group and 12.64 ± 12.83 mg/mmol creatinine (range, 0.5 78.4) in the MPS group.

In the AMD 3100-treated animals, the GAG level in synovial fluid was 0.51 ± 0.09 μg/ml, which was significantly lower than that in the primary OA (0.66 ± 0.05 μg/ml; P = 0.006), and the PBS-treated groups (0.62 ± 0.10 μg/ml; P = 0.045).

Quantitative assessment of GAG synthesis revealed significantly enhanced GAG levels of all treatment groups that received IHH relative to controls, while major differences in the pattern of GAG synthesis over time among the chondrogenic groups IHH, IHH + TGF-β1, or IHH + BMP-2 could not be resolved.

Biochemical measures included urine glycosaminoglycan (GAG) levels, which although elevated showed a decline correlating with age (p < 0.0001) and approached normal values in older subjects.

Results showed that idursulfase, at several doses and at several dosing frequencies, caused a reduction in tissue and urine GAG levels in a dose-dependent manner.

Treated cats had a significant decrease in the brain GAG levels relative to untreated MPS I cats and a paradoxical decrease relative to normal cats.

The purpose of the studies presented here was to describe some of the preclinical development of idursulfase using the I2S knock-out mouse model of MPS II designed to study the effect of dose and various dosing regimens of idursulfase on urine and tissue GAG levels.